AR121618A1 - Compuestos inhibidores de phd, composiciones y métodos de uso - Google Patents
Compuestos inhibidores de phd, composiciones y métodos de usoInfo
- Publication number
- AR121618A1 AR121618A1 ARP210100691A ARP210100691A AR121618A1 AR 121618 A1 AR121618 A1 AR 121618A1 AR P210100691 A ARP210100691 A AR P210100691A AR P210100691 A ARP210100691 A AR P210100691A AR 121618 A1 AR121618 A1 AR 121618A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- formula
- pulmonary
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000018578 heart valve disease Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona, en parte, nuevos inhibidores de moléculas pequeñas de PHD, que tienen una estructura de acuerdo con la fórmula (1), y subfórmulas de estos; o una sal farmacéuticamente aceptable de estos. Los compuestos proporcionados en la presente descripción pueden ser útiles para el tratamiento de enfermedades que incluyen enfermedades cardíacas (p. ej., enfermedad cardíaca isquémica, insuficiencia cardíaca congestiva, y enfermedad cardíaca valvular), pulmonares (p. ej., lesión pulmonar aguda, hipertensión pulmonar, fibrosis pulmonar, y enfermedad pulmonar obstructiva crónica), hepáticas (p. ej., insuficiencia hepática aguda y fibrosis hepática y cirrosis) y renales (p. ej., lesión renal aguda y enfermedad renal crónica). Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de estos, en donde: Ar¹ es fenilo o un heteroarilo que contiene nitrógeno de seis miembros, en donde dicho fenilo o heteroarilo se sustituye opcionalmente con halógeno, CN, OH, alquilo C₁₋₃ opcionalmente sustituido con uno o más halógenos, o alcoxi C₁₋₃; R² es H o alquilo C₁₋₃; Ar² es un heteroarilo que contiene nitrógeno de seis miembros, opcionalmente sustituido con halógeno, OH, amina, o alquilo C₁₋₃; R⁴ es hidrógeno o alquilo C₁₋₄; y en donde la fórmula (1) excluye los siguientes compuestos: del grupo de fórmulas (2).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992585P | 2020-03-20 | 2020-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121618A1 true AR121618A1 (es) | 2022-06-22 |
Family
ID=75639962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100691A AR121618A1 (es) | 2020-03-20 | 2021-03-19 | Compuestos inhibidores de phd, composiciones y métodos de uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230227426A1 (es) |
| EP (1) | EP4121425A1 (es) |
| JP (1) | JP7768890B2 (es) |
| KR (1) | KR20220156889A (es) |
| CN (2) | CN119823097A (es) |
| AR (1) | AR121618A1 (es) |
| AU (1) | AU2021239378A1 (es) |
| BR (1) | BR112022018877A2 (es) |
| CA (1) | CA3176140A1 (es) |
| CO (1) | CO2022014490A2 (es) |
| IL (1) | IL296631A (es) |
| MX (1) | MX2022011123A (es) |
| TW (1) | TW202140443A (es) |
| WO (1) | WO2021188936A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3790863A1 (en) | 2018-05-09 | 2021-03-17 | Akebia Therapeutics Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| US9604961B2 (en) * | 2012-12-06 | 2017-03-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| PT2978752T (pt) * | 2013-03-29 | 2018-03-09 | Takeda Pharmaceuticals Co | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e o seu uso como inibidores de phd |
-
2021
- 2021-03-19 AU AU2021239378A patent/AU2021239378A1/en active Pending
- 2021-03-19 AR ARP210100691A patent/AR121618A1/es unknown
- 2021-03-19 IL IL296631A patent/IL296631A/en unknown
- 2021-03-19 WO PCT/US2021/023219 patent/WO2021188936A1/en not_active Ceased
- 2021-03-19 TW TW110109982A patent/TW202140443A/zh unknown
- 2021-03-19 EP EP21720873.5A patent/EP4121425A1/en active Pending
- 2021-03-19 US US17/906,650 patent/US20230227426A1/en active Pending
- 2021-03-19 CA CA3176140A patent/CA3176140A1/en active Pending
- 2021-03-19 CN CN202510216379.8A patent/CN119823097A/zh active Pending
- 2021-03-19 CN CN202180034124.XA patent/CN115551845B/zh active Active
- 2021-03-19 BR BR112022018877A patent/BR112022018877A2/pt unknown
- 2021-03-19 JP JP2022556170A patent/JP7768890B2/ja active Active
- 2021-03-19 KR KR1020227036362A patent/KR20220156889A/ko active Pending
- 2021-03-19 MX MX2022011123A patent/MX2022011123A/es unknown
-
2022
- 2022-10-12 CO CONC2022/0014490A patent/CO2022014490A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL296631A (en) | 2022-11-01 |
| CN115551845B (zh) | 2025-02-28 |
| KR20220156889A (ko) | 2022-11-28 |
| JP2023518953A (ja) | 2023-05-09 |
| CA3176140A1 (en) | 2021-09-23 |
| TW202140443A (zh) | 2021-11-01 |
| WO2021188936A1 (en) | 2021-09-23 |
| CN119823097A (zh) | 2025-04-15 |
| AU2021239378A1 (en) | 2022-11-17 |
| EP4121425A1 (en) | 2023-01-25 |
| BR112022018877A2 (pt) | 2022-11-29 |
| CO2022014490A2 (es) | 2022-10-21 |
| JP7768890B2 (ja) | 2025-11-12 |
| MX2022011123A (es) | 2023-01-04 |
| US20230227426A1 (en) | 2023-07-20 |
| CN115551845A (zh) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR121626A1 (es) | Compuestos inhibidores de phd, composiciones y métodos de uso | |
| NI200800008A (es) | Métodos para la neuroprotección | |
| AR088921A2 (es) | PROCESO PARA LA PREPARACION DE DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTA mGluR5, COMPOSICIONES Y USO DE LOS COMPUESTOS | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| JP2010528089A5 (es) | ||
| AR096902A1 (es) | Derivados de triazina y pirimidina como inhibidores de la idh1 y/o idh2 mutantes y su uso en el tratamiento del cáncer | |
| EA200201141A1 (ru) | Производные тропана, полезные для терапии | |
| AR094887A1 (es) | Derivado de tetrahidroimidazol[1,5-d][1,4]oxazepina | |
| AR077969A1 (es) | Derivados de (tio)morfolina comomoduladores de s1p | |
| AR121618A1 (es) | Compuestos inhibidores de phd, composiciones y métodos de uso | |
| RU2007148217A (ru) | Получение производных n-фенил-2-пиримидинамина | |
| AR120697A1 (es) | Inhibidores de braf como rompedores de la paradoja | |
| AR082135A1 (es) | Derivados de espiro-piperidina como moduladores s1p | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| MEP24208A (en) | Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics | |
| AR120150A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO4950515A1 (es) | Nuevos derivados de la quinolina para uso medicinal | |
| ME02370B (me) | Halogenovani derivati benzamida | |
| AR118557A1 (es) | Quelantes de hierro derivados del ácido 4-(2,4-bis(2-hidroxifenil)-1h-imidazol-1-il)benzoico | |
| JP2003221386A5 (es) | ||
| BR112022002674A2 (pt) | Derivado de 2-aminoquinazolinona | |
| AR121621A1 (es) | Compuestos inhibidores de phd, composiciones y métodos de uso | |
| AR119162A1 (es) | Derivados de piridin-3-ilo | |
| CO5680413A2 (es) | Aminoacidos con afinidad por la proteina c2 delta |